TC-5619

Drugbox
IUPAC_name = N- [(7S,8S)-7-(pyridin-3-ylmethyl)-1-azabicyclo [2.2.2] octan-8-yl] -1-benzofuran-2-carboxamide


width= 240
CAS_number=
ATC_prefix=
ATC_suffix=
PubChem= 16727410
DrugBank=
C=22 | H=23 | N=3 | O=2
molecular_weight = 361.437
smiles = C1CN2CCC1 [C@@H] ( [C@@H] 2CC3=CN=CC=C3)NC(=O)C4=CC5=CC=CC=C5O4
bioavailability=
metabolism =
elimination_half-life=
excretion =
pregnancy_category =
legal_status =
routes_of_administration=

TC-5619 is a drug developed by Targacept which acts as a partial agonist at the α7 subtype of the neural nicotinic acetylcholine receptors. It showed cognitive enhancing effects in animal studies, and is currently being developed through a collaboration between Targacept and AstraZeneca as a potential treatment for schizophrenia. [ [http://www.targacept.com/wt/page/tc_5619 TC-5619 Cognitive Dysfunction in Schizophrenia] ] Phase I clinical trials have been completed successfully and it is currently in Phase II trials. [ [http://pubs.acs.org/cen/science/86/8637sci2.html Rethinking Schizophrenia] ]

References